Intercept prices IPO; Long-term safety study backs Pfizer pain drug; First tenant for Elk Run?;

Conversations on Twitter :

 @FierceBiotech: New special report: Top diabetes drug pipelines of 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Kythera IPO prices at high end of range (I don't write that very often). More | Follow @JohnCFierce

 @RyanMFierce: GSK will decide whether to grant access to the ID-less patient data based on scientific merit. Sounds subjective, but progress nonetheless. | Follow @RyanMFierce

> Intercept Pharmaceuticals says it has priced its 5 million IPO shares at $15, ahead of underwriting discounts. Release

> Pfizer ($PFE) says its pain drug ALO-02 demonstrated a long-term safety profile which was comparable to similar drugs. Story

> Tengion, a struggling regenerative medicine company in North Carolina, has completed a $15 million note offering with investors Celgene, RA Capital Management, Deerfield Management Company, Bay City Capital and HealthCap. Release

Pharma News

@FiercePharma: India's pharma industry is the country's 2nd-best at making billionaires. More | Follow @FiercePharma

> Minister: Jobs at Sanofi's Toulouse site mostly safe. Story

> Another compounding group shuts amid outbreak. Article

> Glaxo pledges to unveil all trial data, good, bad or ugly. Item

Medical Device News

 @FierceMedDev: As BSX has implied, the job cuts are coming. More | Follow @FierceMedDev

 @MarkHFierce: Not only is angel investing recovering, but much of it seems to be hitting medical device startups. More | Follow @MarkHFierce

 @DamianFierce: Four former Synthes execs have been effectively blacklisted from the life sciences industry. More | Follow @DamianFierce

> J&J's Cordis touts stent for femoral artery disease. Story

> Medical devices drive the start of an angel investor rebound. Item

> Quest Diagnostics slashing 400-600 jobs to save $65M. More

Pharma Manufacturing News

> Novasep investing in another API expansion. News

> Auctus Pharma API plant in India catches fire. Report

> Merck opens $21M Jakarta packaging plant. Story

Vaccines News

> GSK, Aeras partner for TB vaccine trial. More

> Merck taps Vaxxas for Nanopatch vaccine delivery. Story

> Pfizer's Prevnar 13 posts positive late-stage data. Report

> Takeda snaps up LigoCyte for $60M. Item

And Finally… Three years after it was first announced with great fanfare, the Elk Run biotech campus in Minnesota may have just snagged its first tenant. Readers are cautioned, though, that earlier hopes have been repeatedly quashed. Story


Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.